Aspen Neuroscience

Aspen Neuroscience (Ticker: ASPE US) develops cell therapies made from patients’ own cells for neurodegenerative diseases. Its lead experimental therapy, sasineprocel, is being tested in people in an ongoing Phase 1/2a trial for mid-stage to moderately advanced Parkinson’s disease. The company anticipates dosing patients in a Phase 3 trial in the second half of 2027.

Aspen Neuroscience expects to begin trading on Nasdaq on October 30, 2026. The indicative offering range is $15.00–$17.00 per share for 9,375,000 base shares. At the $16.00 indicative midpoint, the offering would represent $150.00 million in gross proceeds, excluding any unexercised over-allotment.

Underwriters include Leerink Partners, Piper Sandler and Stifel.